nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—TNK2—liver cancer	0.139	0.322	CbGaD
Dasatinib—SRMS—liver cancer	0.139	0.322	CbGaD
Dasatinib—ZAK—Sorafenib—liver cancer	0.105	0.286	CbGbCtD
Dasatinib—MAPK14—liver cancer	0.0896	0.208	CbGaD
Dasatinib—ABL1—liver cancer	0.0471	0.109	CbGaD
Dasatinib—EPHB6—Sorafenib—liver cancer	0.0385	0.105	CbGbCtD
Dasatinib—KIT—Sorafenib—liver cancer	0.0346	0.0944	CbGbCtD
Dasatinib—CSF1R—Sorafenib—liver cancer	0.0346	0.0944	CbGbCtD
Dasatinib—PDGFRA—Sorafenib—liver cancer	0.0346	0.0944	CbGbCtD
Dasatinib—PDGFRB—Sorafenib—liver cancer	0.0315	0.0859	CbGbCtD
Dasatinib—MAP2K5—Sorafenib—liver cancer	0.0315	0.0859	CbGbCtD
Dasatinib—MAP3K19—Sorafenib—liver cancer	0.0289	0.079	CbGbCtD
Dasatinib—CYP1A1—liver cancer	0.0164	0.038	CbGaD
Dasatinib—CYP1B1—Doxorubicin—liver cancer	0.00729	0.0199	CbGbCtD
Dasatinib—ABCG2—Sorafenib—liver cancer	0.00571	0.0156	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—liver cancer	0.00347	0.00946	CbGbCtD
Dasatinib—CYP3A5—Sorafenib—liver cancer	0.00316	0.00864	CbGbCtD
Dasatinib—CYP1A2—Sorafenib—liver cancer	0.00235	0.00643	CbGbCtD
Dasatinib—ABCB1—Sorafenib—liver cancer	0.00206	0.00562	CbGbCtD
Dasatinib—SRMS—gall bladder—liver cancer	0.00169	0.0691	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—liver cancer	0.00125	0.00341	CbGbCtD
Dasatinib—CYP3A4—Sorafenib—liver cancer	0.00123	0.00337	CbGbCtD
Dasatinib—STAT5B—embryo—liver cancer	0.000991	0.0406	CbGeAlD
Dasatinib—TEC—liver—liver cancer	0.000784	0.0321	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—liver cancer	0.000749	0.00204	CbGbCtD
Dasatinib—EPHB3—embryo—liver cancer	0.000721	0.0295	CbGeAlD
Dasatinib—PDGFRA—gall bladder—liver cancer	0.000719	0.0295	CbGeAlD
Dasatinib—CSK—embryo—liver cancer	0.000671	0.0275	CbGeAlD
Dasatinib—EPHB1—liver—liver cancer	0.000616	0.0252	CbGeAlD
Dasatinib—EPHA4—embryo—liver cancer	0.000602	0.0247	CbGeAlD
Dasatinib—ERBB3—embryo—liver cancer	0.000596	0.0244	CbGeAlD
Dasatinib—KIT—gall bladder—liver cancer	0.000575	0.0236	CbGeAlD
Dasatinib—PDGFRB—gall bladder—liver cancer	0.000562	0.023	CbGeAlD
Dasatinib—MAPK14—embryo—liver cancer	0.000555	0.0227	CbGeAlD
Dasatinib—FGR—embryo—liver cancer	0.000553	0.0226	CbGeAlD
Dasatinib—SIK2—liver—liver cancer	0.000544	0.0223	CbGeAlD
Dasatinib—FRK—liver—liver cancer	0.00053	0.0217	CbGeAlD
Dasatinib—JAK2—embryo—liver cancer	0.000522	0.0214	CbGeAlD
Dasatinib—FYN—embryo—liver cancer	0.000515	0.0211	CbGeAlD
Dasatinib—STAT5B—liver—liver cancer	0.000458	0.0188	CbGeAlD
Dasatinib—PDGFRA—embryo—liver cancer	0.000456	0.0187	CbGeAlD
Dasatinib—SRC—embryo—liver cancer	0.000447	0.0183	CbGeAlD
Dasatinib—SIK3—liver—liver cancer	0.000412	0.0169	CbGeAlD
Dasatinib—CSF1R—embryo—liver cancer	0.000402	0.0165	CbGeAlD
Dasatinib—ZAK—liver—liver cancer	0.000383	0.0157	CbGeAlD
Dasatinib—LYN—liver—liver cancer	0.000373	0.0153	CbGeAlD
Dasatinib—BTK—liver—liver cancer	0.000365	0.015	CbGeAlD
Dasatinib—KIT—embryo—liver cancer	0.000365	0.0149	CbGeAlD
Dasatinib—TNK2—liver—liver cancer	0.00036	0.0148	CbGeAlD
Dasatinib—PDGFRB—embryo—liver cancer	0.000356	0.0146	CbGeAlD
Dasatinib—TESK1—liver—liver cancer	0.000339	0.0139	CbGeAlD
Dasatinib—STK36—liver—liver cancer	0.000333	0.0137	CbGeAlD
Dasatinib—LIMK2—liver—liver cancer	0.000322	0.0132	CbGeAlD
Dasatinib—ABL1—embryo—liver cancer	0.000317	0.013	CbGeAlD
Dasatinib—STK35—liver—liver cancer	0.000312	0.0128	CbGeAlD
Dasatinib—CSK—liver—liver cancer	0.00031	0.0127	CbGeAlD
Dasatinib—HCK—liver—liver cancer	0.000306	0.0126	CbGeAlD
Dasatinib—ABL2—liver—liver cancer	0.000304	0.0125	CbGeAlD
Dasatinib—RIPK2—liver—liver cancer	0.000288	0.0118	CbGeAlD
Dasatinib—SIK1—liver—liver cancer	0.000281	0.0115	CbGeAlD
Dasatinib—ERBB3—liver—liver cancer	0.000276	0.0113	CbGeAlD
Dasatinib—MAP3K2—liver—liver cancer	0.000273	0.0112	CbGeAlD
Dasatinib—MAPK14—liver—liver cancer	0.000257	0.0105	CbGeAlD
Dasatinib—FGR—liver—liver cancer	0.000256	0.0105	CbGeAlD
Dasatinib—LCK—liver—liver cancer	0.000256	0.0105	CbGeAlD
Dasatinib—FMO3—liver—liver cancer	0.000247	0.0101	CbGeAlD
Dasatinib—EPHB4—liver—liver cancer	0.000243	0.00997	CbGeAlD
Dasatinib—JAK2—liver—liver cancer	0.000242	0.0099	CbGeAlD
Dasatinib—EPHA2—liver—liver cancer	0.000239	0.00978	CbGeAlD
Dasatinib—FYN—liver—liver cancer	0.000238	0.00977	CbGeAlD
Dasatinib—MAP3K3—liver—liver cancer	0.000233	0.00954	CbGeAlD
Dasatinib—MAP4K5—liver—liver cancer	0.000233	0.00954	CbGeAlD
Dasatinib—CSK—Daunorubicin—Epirubicin—liver cancer	0.000224	0.127	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—liver cancer	0.000224	0.127	CbGdCrCtD
Dasatinib—YES1—liver—liver cancer	0.000215	0.00881	CbGeAlD
Dasatinib—PDGFRA—liver—liver cancer	0.000211	0.00865	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—liver cancer	0.000207	0.117	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—liver cancer	0.000207	0.117	CbGdCrCtD
Dasatinib—SRC—liver—liver cancer	0.000207	0.00848	CbGeAlD
Dasatinib—MAP2K5—liver—liver cancer	0.00019	0.0078	CbGeAlD
Dasatinib—CSF1R—liver—liver cancer	0.000186	0.00761	CbGeAlD
Dasatinib—KIT—liver—liver cancer	0.000169	0.00691	CbGeAlD
Dasatinib—PDGFRB—liver—liver cancer	0.000165	0.00675	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000156	0.0886	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000156	0.0886	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000156	0.0886	CbGdCrCtD
Dasatinib—ABL1—liver—liver cancer	0.000147	0.00602	CbGeAlD
Dasatinib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000144	0.082	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000144	0.082	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000144	0.082	CbGdCrCtD
Dasatinib—CYP1B1—liver—liver cancer	0.000124	0.0051	CbGeAlD
Dasatinib—Fatigue—Sorafenib—liver cancer	0.000104	0.00162	CcSEcCtD
Dasatinib—Photosensitivity—Epirubicin—liver cancer	0.000103	0.00161	CcSEcCtD
Dasatinib—Constipation—Sorafenib—liver cancer	0.000103	0.00161	CcSEcCtD
Dasatinib—Pain—Sorafenib—liver cancer	0.000103	0.00161	CcSEcCtD
Dasatinib—Pulmonary oedema—Doxorubicin—liver cancer	0.000103	0.00161	CcSEcCtD
Dasatinib—Eczema—Epirubicin—liver cancer	0.000101	0.00158	CcSEcCtD
Dasatinib—Sepsis—Doxorubicin—liver cancer	0.0001	0.00157	CcSEcCtD
Dasatinib—Cardiac failure congestive—Epirubicin—liver cancer	0.0001	0.00156	CcSEcCtD
Dasatinib—ABCB1—embryo—liver cancer	9.87e-05	0.00405	CbGeAlD
Dasatinib—Gastrointestinal pain—Sorafenib—liver cancer	9.86e-05	0.00154	CcSEcCtD
Dasatinib—Thrombophlebitis—Doxorubicin—liver cancer	9.69e-05	0.00151	CcSEcCtD
Dasatinib—Urticaria—Sorafenib—liver cancer	9.58e-05	0.0015	CcSEcCtD
Dasatinib—Photosensitivity—Doxorubicin—liver cancer	9.55e-05	0.00149	CcSEcCtD
Dasatinib—Body temperature increased—Sorafenib—liver cancer	9.53e-05	0.00149	CcSEcCtD
Dasatinib—Abdominal pain—Sorafenib—liver cancer	9.53e-05	0.00149	CcSEcCtD
Dasatinib—Eczema—Doxorubicin—liver cancer	9.33e-05	0.00146	CcSEcCtD
Dasatinib—Cardiac failure—Epirubicin—liver cancer	9.29e-05	0.00145	CcSEcCtD
Dasatinib—ABCG2—liver—liver cancer	9.26e-05	0.00379	CbGeAlD
Dasatinib—Cerebrovascular accident—Epirubicin—liver cancer	9.25e-05	0.00145	CcSEcCtD
Dasatinib—Cardiac failure congestive—Doxorubicin—liver cancer	9.25e-05	0.00145	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	9.07e-05	0.00142	CcSEcCtD
Dasatinib—Affect lability—Epirubicin—liver cancer	8.92e-05	0.00139	CcSEcCtD
Dasatinib—CYP1A2—liver—liver cancer	8.91e-05	0.00365	CbGeAlD
Dasatinib—Hypersensitivity—Sorafenib—liver cancer	8.88e-05	0.00139	CcSEcCtD
Dasatinib—CYP1A1—liver—liver cancer	8.79e-05	0.0036	CbGeAlD
Dasatinib—Face oedema—Epirubicin—liver cancer	8.75e-05	0.00137	CcSEcCtD
Dasatinib—Asthenia—Sorafenib—liver cancer	8.65e-05	0.00135	CcSEcCtD
Dasatinib—Cardiac failure—Doxorubicin—liver cancer	8.6e-05	0.00134	CcSEcCtD
Dasatinib—CYP3A5—liver—liver cancer	8.59e-05	0.00352	CbGeAlD
Dasatinib—Cerebrovascular accident—Doxorubicin—liver cancer	8.56e-05	0.00134	CcSEcCtD
Dasatinib—Pruritus—Sorafenib—liver cancer	8.53e-05	0.00133	CcSEcCtD
Dasatinib—Blood creatinine increased—Epirubicin—liver cancer	8.49e-05	0.00133	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	8.39e-05	0.00131	CcSEcCtD
Dasatinib—Dry skin—Epirubicin—liver cancer	8.31e-05	0.0013	CcSEcCtD
Dasatinib—Affect lability—Doxorubicin—liver cancer	8.26e-05	0.00129	CcSEcCtD
Dasatinib—Hypokalaemia—Epirubicin—liver cancer	8.25e-05	0.00129	CcSEcCtD
Dasatinib—Diarrhoea—Sorafenib—liver cancer	8.25e-05	0.00129	CcSEcCtD
Dasatinib—Breast disorder—Epirubicin—liver cancer	8.19e-05	0.00128	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	8.16e-05	0.00128	CcSEcCtD
Dasatinib—Face oedema—Doxorubicin—liver cancer	8.1e-05	0.00127	CcSEcCtD
Dasatinib—Gastritis—Epirubicin—liver cancer	8.02e-05	0.00125	CcSEcCtD
Dasatinib—Muscular weakness—Epirubicin—liver cancer	8e-05	0.00125	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Epirubicin—liver cancer	8e-05	0.00125	CcSEcCtD
Dasatinib—Dizziness—Sorafenib—liver cancer	7.97e-05	0.00125	CcSEcCtD
Dasatinib—Abdominal distension—Epirubicin—liver cancer	7.89e-05	0.00123	CcSEcCtD
Dasatinib—Blood creatinine increased—Doxorubicin—liver cancer	7.86e-05	0.00123	CcSEcCtD
Dasatinib—Asthma—Epirubicin—liver cancer	7.84e-05	0.00122	CcSEcCtD
Dasatinib—Dysphagia—Epirubicin—liver cancer	7.84e-05	0.00122	CcSEcCtD
Dasatinib—Dry skin—Doxorubicin—liver cancer	7.69e-05	0.0012	CcSEcCtD
Dasatinib—Pancreatitis—Epirubicin—liver cancer	7.68e-05	0.0012	CcSEcCtD
Dasatinib—Vomiting—Sorafenib—liver cancer	7.67e-05	0.0012	CcSEcCtD
Dasatinib—Hypokalaemia—Doxorubicin—liver cancer	7.63e-05	0.00119	CcSEcCtD
Dasatinib—Angina pectoris—Epirubicin—liver cancer	7.63e-05	0.00119	CcSEcCtD
Dasatinib—Rash—Sorafenib—liver cancer	7.6e-05	0.00119	CcSEcCtD
Dasatinib—Dermatitis—Sorafenib—liver cancer	7.6e-05	0.00119	CcSEcCtD
Dasatinib—Breast disorder—Doxorubicin—liver cancer	7.58e-05	0.00118	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	7.55e-05	0.00118	CcSEcCtD
Dasatinib—Headache—Sorafenib—liver cancer	7.55e-05	0.00118	CcSEcCtD
Dasatinib—Pancytopenia—Epirubicin—liver cancer	7.44e-05	0.00116	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—liver cancer	7.42e-05	0.00116	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—liver cancer	7.4e-05	0.00116	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	7.4e-05	0.00116	CcSEcCtD
Dasatinib—Neutropenia—Epirubicin—liver cancer	7.33e-05	0.00114	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—liver cancer	7.3e-05	0.00114	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Epirubicin—liver cancer	7.28e-05	0.00114	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—liver cancer	7.25e-05	0.00113	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—liver cancer	7.25e-05	0.00113	CcSEcCtD
Dasatinib—Pollakiuria—Epirubicin—liver cancer	7.24e-05	0.00113	CcSEcCtD
Dasatinib—Nausea—Sorafenib—liver cancer	7.16e-05	0.00112	CcSEcCtD
Dasatinib—Photosensitivity reaction—Epirubicin—liver cancer	7.15e-05	0.00112	CcSEcCtD
Dasatinib—Weight increased—Epirubicin—liver cancer	7.13e-05	0.00111	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—liver cancer	7.11e-05	0.00111	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—liver cancer	7.09e-05	0.00111	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—liver cancer	7.06e-05	0.0011	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—liver cancer	7.03e-05	0.0011	CcSEcCtD
Dasatinib—Infestation—Epirubicin—liver cancer	6.99e-05	0.00109	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—liver cancer	6.99e-05	0.00109	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—liver cancer	6.89e-05	0.00108	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—liver cancer	6.87e-05	0.00107	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—liver cancer	6.85e-05	0.00107	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—liver cancer	6.81e-05	0.00106	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—liver cancer	6.79e-05	0.00106	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—liver cancer	6.78e-05	0.00106	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—liver cancer	6.74e-05	0.00105	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—liver cancer	6.7e-05	0.00105	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—liver cancer	6.66e-05	0.00104	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—liver cancer	6.62e-05	0.00103	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—liver cancer	6.61e-05	0.00103	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—liver cancer	6.6e-05	0.00103	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—liver cancer	6.59e-05	0.00103	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—liver cancer	6.56e-05	0.00102	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—liver cancer	6.5e-05	0.00102	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—liver cancer	6.46e-05	0.00101	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—liver cancer	6.46e-05	0.00101	CcSEcCtD
Dasatinib—CYP3A4—liver—liver cancer	6.45e-05	0.00264	CbGeAlD
Dasatinib—Renal failure—Doxorubicin—liver cancer	6.35e-05	0.000993	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—liver cancer	6.34e-05	0.00099	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—liver cancer	6.3e-05	0.000985	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—liver cancer	6.3e-05	0.000984	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—liver cancer	6.28e-05	0.000982	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—liver cancer	6.27e-05	0.00098	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—liver cancer	6.27e-05	0.00098	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—liver cancer	6.19e-05	0.000968	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—liver cancer	6.18e-05	0.000965	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—liver cancer	6.16e-05	0.000963	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—liver cancer	6.16e-05	0.000963	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—liver cancer	6.15e-05	0.00096	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—liver cancer	6.11e-05	0.000955	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—liver cancer	6.1e-05	0.000953	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—liver cancer	6.04e-05	0.000944	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—liver cancer	5.93e-05	0.000926	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—liver cancer	5.86e-05	0.000916	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—liver cancer	5.85e-05	0.000914	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—liver cancer	5.83e-05	0.000911	CcSEcCtD
Dasatinib—Flushing—Epirubicin—liver cancer	5.82e-05	0.000909	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—liver cancer	5.82e-05	0.000909	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—liver cancer	5.8e-05	0.000907	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—liver cancer	5.8e-05	0.000907	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—liver cancer	5.73e-05	0.000895	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—liver cancer	5.72e-05	0.000893	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—liver cancer	5.7e-05	0.000891	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—liver cancer	5.69e-05	0.000889	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—liver cancer	5.69e-05	0.000889	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—liver cancer	5.67e-05	0.000885	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—liver cancer	5.65e-05	0.000883	CcSEcCtD
Dasatinib—Chills—Epirubicin—liver cancer	5.63e-05	0.000879	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—liver cancer	5.6e-05	0.000875	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—liver cancer	5.59e-05	0.000874	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—liver cancer	5.54e-05	0.000866	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—liver cancer	5.49e-05	0.000858	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—liver cancer	5.49e-05	0.000857	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—liver cancer	5.46e-05	0.000853	CcSEcCtD
Dasatinib—Erythema—Epirubicin—liver cancer	5.46e-05	0.000853	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—liver cancer	5.42e-05	0.000847	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—liver cancer	5.41e-05	0.000845	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—liver cancer	5.39e-05	0.000841	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—liver cancer	5.39e-05	0.000841	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—liver cancer	5.35e-05	0.000835	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—liver cancer	5.27e-05	0.000823	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—liver cancer	5.25e-05	0.00082	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—liver cancer	5.24e-05	0.000819	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—liver cancer	5.23e-05	0.000817	CcSEcCtD
Dasatinib—Chills—Doxorubicin—liver cancer	5.21e-05	0.000813	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—liver cancer	5.18e-05	0.00081	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—liver cancer	5.15e-05	0.000804	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—liver cancer	5.13e-05	0.000801	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—liver cancer	5.08e-05	0.000794	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—liver cancer	5.07e-05	0.000791	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—liver cancer	5.05e-05	0.000789	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—liver cancer	5.05e-05	0.000789	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—liver cancer	5.05e-05	0.000788	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—liver cancer	4.95e-05	0.000773	CcSEcCtD
Dasatinib—Malaise—Epirubicin—liver cancer	4.92e-05	0.000769	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—liver cancer	4.91e-05	0.000766	CcSEcCtD
Dasatinib—Syncope—Epirubicin—liver cancer	4.9e-05	0.000765	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—liver cancer	4.86e-05	0.000759	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—liver cancer	4.83e-05	0.000754	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—liver cancer	4.8e-05	0.00075	CcSEcCtD
Dasatinib—Cough—Epirubicin—liver cancer	4.76e-05	0.000744	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—liver cancer	4.76e-05	0.000744	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—liver cancer	4.73e-05	0.000739	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—liver cancer	4.71e-05	0.000736	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—liver cancer	4.69e-05	0.000732	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—liver cancer	4.67e-05	0.000729	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—liver cancer	4.65e-05	0.000726	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—liver cancer	4.65e-05	0.000726	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—liver cancer	4.65e-05	0.000726	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—liver cancer	4.63e-05	0.000724	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	4.62e-05	0.000721	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—liver cancer	4.59e-05	0.000717	CcSEcCtD
Dasatinib—ABCB1—liver—liver cancer	4.56e-05	0.00187	CbGeAlD
Dasatinib—Malaise—Doxorubicin—liver cancer	4.56e-05	0.000712	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—liver cancer	4.54e-05	0.000709	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—liver cancer	4.53e-05	0.000708	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—liver cancer	4.49e-05	0.000702	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—liver cancer	4.46e-05	0.000697	CcSEcCtD
Dasatinib—Oedema—Epirubicin—liver cancer	4.46e-05	0.000696	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—liver cancer	4.44e-05	0.000694	CcSEcCtD
Dasatinib—Infection—Epirubicin—liver cancer	4.43e-05	0.000692	CcSEcCtD
Dasatinib—Cough—Doxorubicin—liver cancer	4.41e-05	0.000689	CcSEcCtD
Dasatinib—Shock—Epirubicin—liver cancer	4.38e-05	0.000685	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—liver cancer	4.38e-05	0.000684	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—liver cancer	4.37e-05	0.000683	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—liver cancer	4.36e-05	0.000682	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—liver cancer	4.36e-05	0.000681	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—liver cancer	4.35e-05	0.000679	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—liver cancer	4.33e-05	0.000676	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—liver cancer	4.31e-05	0.000673	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—liver cancer	4.3e-05	0.000672	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—liver cancer	4.3e-05	0.000672	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—liver cancer	4.3e-05	0.000672	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—liver cancer	4.29e-05	0.00067	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	4.27e-05	0.000667	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—liver cancer	4.25e-05	0.000664	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—liver cancer	4.25e-05	0.000664	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—liver cancer	4.16e-05	0.00065	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—liver cancer	4.16e-05	0.000649	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—liver cancer	4.12e-05	0.000644	CcSEcCtD
Dasatinib—Infection—Doxorubicin—liver cancer	4.1e-05	0.00064	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—liver cancer	4.06e-05	0.000634	CcSEcCtD
Dasatinib—Shock—Doxorubicin—liver cancer	4.06e-05	0.000634	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—liver cancer	4.04e-05	0.000632	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—liver cancer	4.04e-05	0.000631	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—liver cancer	4.03e-05	0.00063	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—liver cancer	4.02e-05	0.000629	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—liver cancer	4e-05	0.000626	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—liver cancer	3.99e-05	0.000623	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—liver cancer	3.97e-05	0.000621	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—liver cancer	3.96e-05	0.000619	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—liver cancer	3.93e-05	0.000614	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—liver cancer	3.92e-05	0.000613	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—liver cancer	3.87e-05	0.000605	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—liver cancer	3.85e-05	0.000602	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—liver cancer	3.85e-05	0.000601	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—liver cancer	3.84e-05	0.0006	CcSEcCtD
Dasatinib—Pain—Epirubicin—liver cancer	3.81e-05	0.000595	CcSEcCtD
Dasatinib—Constipation—Epirubicin—liver cancer	3.81e-05	0.000595	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	3.76e-05	0.000587	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—liver cancer	3.73e-05	0.000583	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—liver cancer	3.68e-05	0.000574	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—liver cancer	3.67e-05	0.000574	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—liver cancer	3.67e-05	0.000573	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—liver cancer	3.64e-05	0.000569	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—liver cancer	3.63e-05	0.000567	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—liver cancer	3.58e-05	0.00056	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—liver cancer	3.56e-05	0.000556	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—liver cancer	3.55e-05	0.000555	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—liver cancer	3.54e-05	0.000553	CcSEcCtD
Dasatinib—Pain—Doxorubicin—liver cancer	3.53e-05	0.000551	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—liver cancer	3.53e-05	0.000551	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—liver cancer	3.52e-05	0.00055	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—liver cancer	3.52e-05	0.00055	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—liver cancer	3.4e-05	0.000531	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—liver cancer	3.37e-05	0.000527	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—liver cancer	3.28e-05	0.000513	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—liver cancer	3.28e-05	0.000512	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—liver cancer	3.26e-05	0.000509	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—liver cancer	3.26e-05	0.000509	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—liver cancer	3.2e-05	0.000499	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—liver cancer	3.15e-05	0.000492	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—liver cancer	3.05e-05	0.000476	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—liver cancer	3.04e-05	0.000475	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—liver cancer	2.96e-05	0.000462	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—liver cancer	2.95e-05	0.00046	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—liver cancer	2.92e-05	0.000456	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—liver cancer	2.83e-05	0.000443	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—liver cancer	2.82e-05	0.000441	CcSEcCtD
Dasatinib—Rash—Epirubicin—liver cancer	2.81e-05	0.000439	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—liver cancer	2.81e-05	0.000439	CcSEcCtD
Dasatinib—Headache—Epirubicin—liver cancer	2.79e-05	0.000436	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—liver cancer	2.73e-05	0.000426	CcSEcCtD
Dasatinib—Nausea—Epirubicin—liver cancer	2.65e-05	0.000413	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—liver cancer	2.62e-05	0.00041	CcSEcCtD
Dasatinib—Rash—Doxorubicin—liver cancer	2.6e-05	0.000406	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—liver cancer	2.6e-05	0.000406	CcSEcCtD
Dasatinib—Headache—Doxorubicin—liver cancer	2.58e-05	0.000403	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—liver cancer	2.45e-05	0.000383	CcSEcCtD
Dasatinib—CYP3A5—Metabolism—PPARG—liver cancer	4.75e-07	4.22e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—liver cancer	4.74e-07	4.22e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—liver cancer	4.74e-07	4.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A1—liver cancer	4.74e-07	4.22e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—liver cancer	4.74e-07	4.22e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—liver cancer	4.72e-07	4.2e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—liver cancer	4.72e-07	4.2e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—liver cancer	4.72e-07	4.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—liver cancer	4.7e-07	4.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—liver cancer	4.69e-07	4.17e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK8—liver cancer	4.68e-07	4.17e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—liver cancer	4.66e-07	4.15e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—liver cancer	4.66e-07	4.14e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—liver cancer	4.65e-07	4.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RAF1—liver cancer	4.65e-07	4.14e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—liver cancer	4.65e-07	4.14e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—liver cancer	4.64e-07	4.13e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—liver cancer	4.64e-07	4.13e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—liver cancer	4.63e-07	4.12e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—liver cancer	4.62e-07	4.12e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CD—liver cancer	4.61e-07	4.1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK8—liver cancer	4.61e-07	4.1e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—liver cancer	4.6e-07	4.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—liver cancer	4.59e-07	4.09e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—liver cancer	4.58e-07	4.08e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—liver cancer	4.57e-07	4.07e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—liver cancer	4.56e-07	4.06e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—liver cancer	4.56e-07	4.06e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—liver cancer	4.56e-07	4.06e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—liver cancer	4.55e-07	4.05e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—liver cancer	4.55e-07	4.05e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CB—liver cancer	4.54e-07	4.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MTOR—liver cancer	4.54e-07	4.04e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—liver cancer	4.53e-07	4.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—liver cancer	4.52e-07	4.02e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—liver cancer	4.51e-07	4.02e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—liver cancer	4.51e-07	4.01e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—liver cancer	4.5e-07	4.01e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	4.5e-07	4e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—liver cancer	4.49e-07	4e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—liver cancer	4.48e-07	3.99e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—liver cancer	4.47e-07	3.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMD10—liver cancer	4.44e-07	3.95e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMA4—liver cancer	4.44e-07	3.95e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK8—liver cancer	4.44e-07	3.95e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—liver cancer	4.43e-07	3.95e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—liver cancer	4.42e-07	3.93e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	4.41e-07	3.93e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—liver cancer	4.4e-07	3.92e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—liver cancer	4.39e-07	3.91e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—liver cancer	4.38e-07	3.9e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK8—liver cancer	4.38e-07	3.9e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—liver cancer	4.38e-07	3.9e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—liver cancer	4.37e-07	3.89e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—liver cancer	4.37e-07	3.89e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—liver cancer	4.37e-07	3.89e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—liver cancer	4.36e-07	3.88e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—liver cancer	4.36e-07	3.88e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—liver cancer	4.34e-07	3.86e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARA—liver cancer	4.33e-07	3.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—liver cancer	4.33e-07	3.85e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—liver cancer	4.32e-07	3.85e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—liver cancer	4.32e-07	3.85e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GOT2—liver cancer	4.32e-07	3.85e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—liver cancer	4.3e-07	3.83e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—liver cancer	4.28e-07	3.81e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—liver cancer	4.28e-07	3.81e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—liver cancer	4.28e-07	3.81e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—liver cancer	4.27e-07	3.8e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—liver cancer	4.27e-07	3.8e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—liver cancer	4.26e-07	3.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—liver cancer	4.26e-07	3.79e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—liver cancer	4.25e-07	3.78e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—liver cancer	4.21e-07	3.75e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—liver cancer	4.21e-07	3.75e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—liver cancer	4.2e-07	3.74e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—liver cancer	4.2e-07	3.74e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—liver cancer	4.19e-07	3.73e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—liver cancer	4.18e-07	3.72e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—liver cancer	4.17e-07	3.72e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—liver cancer	4.17e-07	3.71e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—liver cancer	4.17e-07	3.71e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—liver cancer	4.12e-07	3.67e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—liver cancer	4.12e-07	3.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—liver cancer	4.12e-07	3.66e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—liver cancer	4.11e-07	3.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—liver cancer	4.1e-07	3.65e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—liver cancer	4.08e-07	3.64e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—liver cancer	4.06e-07	3.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2E1—liver cancer	4.06e-07	3.62e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—liver cancer	4.06e-07	3.62e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—liver cancer	4.06e-07	3.61e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—liver cancer	4.06e-07	3.61e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	4.05e-07	3.61e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—liver cancer	4.05e-07	3.6e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—liver cancer	4.04e-07	3.6e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—liver cancer	4.04e-07	3.6e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—liver cancer	4.03e-07	3.59e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—liver cancer	4.02e-07	3.58e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—liver cancer	4.02e-07	3.58e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—liver cancer	4.02e-07	3.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—liver cancer	4.02e-07	3.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—liver cancer	4.02e-07	3.58e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—liver cancer	4.01e-07	3.57e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—liver cancer	4.01e-07	3.57e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—liver cancer	4e-07	3.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—liver cancer	3.99e-07	3.55e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—liver cancer	3.99e-07	3.55e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—liver cancer	3.98e-07	3.54e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—liver cancer	3.97e-07	3.53e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—liver cancer	3.96e-07	3.52e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—liver cancer	3.95e-07	3.52e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—liver cancer	3.95e-07	3.51e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—liver cancer	3.93e-07	3.5e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—liver cancer	3.92e-07	3.49e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—liver cancer	3.91e-07	3.48e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—liver cancer	3.91e-07	3.48e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—liver cancer	3.88e-07	3.45e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—liver cancer	3.84e-07	3.42e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	3.83e-07	3.41e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—liver cancer	3.81e-07	3.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYCS—liver cancer	3.8e-07	3.38e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—liver cancer	3.79e-07	3.37e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—liver cancer	3.79e-07	3.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—liver cancer	3.78e-07	3.37e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—liver cancer	3.77e-07	3.36e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—liver cancer	3.77e-07	3.36e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—liver cancer	3.77e-07	3.35e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—liver cancer	3.76e-07	3.35e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—liver cancer	3.75e-07	3.34e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—liver cancer	3.74e-07	3.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GGT1—liver cancer	3.73e-07	3.32e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GOT1—liver cancer	3.73e-07	3.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—liver cancer	3.72e-07	3.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—liver cancer	3.71e-07	3.3e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—liver cancer	3.71e-07	3.3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—liver cancer	3.7e-07	3.3e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—liver cancer	3.7e-07	3.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—liver cancer	3.7e-07	3.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—liver cancer	3.69e-07	3.29e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—liver cancer	3.69e-07	3.28e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—liver cancer	3.67e-07	3.27e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—liver cancer	3.66e-07	3.25e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—liver cancer	3.62e-07	3.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—liver cancer	3.6e-07	3.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—liver cancer	3.59e-07	3.2e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—liver cancer	3.58e-07	3.19e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—liver cancer	3.58e-07	3.19e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—liver cancer	3.56e-07	3.17e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—liver cancer	3.56e-07	3.17e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—liver cancer	3.54e-07	3.15e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—liver cancer	3.54e-07	3.15e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—liver cancer	3.53e-07	3.14e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—liver cancer	3.52e-07	3.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—liver cancer	3.51e-07	3.12e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—liver cancer	3.51e-07	3.12e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—liver cancer	3.5e-07	3.11e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—liver cancer	3.5e-07	3.11e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—liver cancer	3.5e-07	3.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—liver cancer	3.49e-07	3.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—liver cancer	3.48e-07	3.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—liver cancer	3.48e-07	3.1e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARA—liver cancer	3.46e-07	3.08e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	3.45e-07	3.07e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—liver cancer	3.44e-07	3.06e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—liver cancer	3.4e-07	3.02e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—liver cancer	3.39e-07	3.02e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—liver cancer	3.38e-07	3.01e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—liver cancer	3.36e-07	2.99e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—liver cancer	3.35e-07	2.98e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—liver cancer	3.34e-07	2.97e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—liver cancer	3.32e-07	2.96e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—liver cancer	3.3e-07	2.94e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—liver cancer	3.3e-07	2.94e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—liver cancer	3.27e-07	2.91e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—liver cancer	3.26e-07	2.9e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—liver cancer	3.26e-07	2.9e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—liver cancer	3.25e-07	2.89e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—liver cancer	3.24e-07	2.88e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—liver cancer	3.23e-07	2.87e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—liver cancer	3.22e-07	2.87e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—liver cancer	3.22e-07	2.86e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—liver cancer	3.21e-07	2.85e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—liver cancer	3.2e-07	2.85e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—liver cancer	3.19e-07	2.84e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—liver cancer	3.16e-07	2.81e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—liver cancer	3.14e-07	2.79e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—liver cancer	3.13e-07	2.78e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—liver cancer	3.12e-07	2.78e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.11e-07	2.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—liver cancer	3.11e-07	2.76e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—liver cancer	3.1e-07	2.76e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—liver cancer	3.1e-07	2.76e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—liver cancer	3.1e-07	2.76e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—liver cancer	3.08e-07	2.74e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—liver cancer	3.08e-07	2.74e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—liver cancer	3.06e-07	2.72e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—liver cancer	3.05e-07	2.72e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—liver cancer	3.01e-07	2.68e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—liver cancer	2.99e-07	2.66e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—liver cancer	2.96e-07	2.64e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—liver cancer	2.96e-07	2.64e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—liver cancer	2.94e-07	2.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—liver cancer	2.92e-07	2.6e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—liver cancer	2.92e-07	2.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—liver cancer	2.89e-07	2.57e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—liver cancer	2.88e-07	2.56e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—liver cancer	2.88e-07	2.56e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—liver cancer	2.86e-07	2.54e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—liver cancer	2.86e-07	2.54e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—liver cancer	2.84e-07	2.53e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—liver cancer	2.83e-07	2.52e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—liver cancer	2.82e-07	2.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—liver cancer	2.8e-07	2.49e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—liver cancer	2.77e-07	2.46e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—liver cancer	2.76e-07	2.45e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—liver cancer	2.72e-07	2.42e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—liver cancer	2.72e-07	2.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—liver cancer	2.68e-07	2.38e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARA—liver cancer	2.67e-07	2.38e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—liver cancer	2.67e-07	2.37e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—liver cancer	2.62e-07	2.33e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—liver cancer	2.61e-07	2.33e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—liver cancer	2.6e-07	2.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—liver cancer	2.58e-07	2.3e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—liver cancer	2.57e-07	2.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—liver cancer	2.56e-07	2.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—liver cancer	2.45e-07	2.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—liver cancer	2.45e-07	2.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—liver cancer	2.37e-07	2.11e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—liver cancer	2.3e-07	2.04e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—liver cancer	2.29e-07	2.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—liver cancer	2.27e-07	2.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—liver cancer	2.27e-07	2.02e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—liver cancer	2.26e-07	2.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—liver cancer	2.21e-07	1.96e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—liver cancer	2.17e-07	1.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—liver cancer	2.17e-07	1.93e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—liver cancer	2.01e-07	1.79e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—liver cancer	2e-07	1.78e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—liver cancer	1.98e-07	1.77e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—liver cancer	1.88e-07	1.67e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—liver cancer	1.77e-07	1.58e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—liver cancer	1.75e-07	1.56e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—liver cancer	1.73e-07	1.54e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—liver cancer	1.42e-07	1.26e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—liver cancer	1.38e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—liver cancer	1.13e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—liver cancer	1.07e-07	9.51e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—liver cancer	8.72e-08	7.77e-07	CbGpPWpGaD
